MIRA INFORM REPORT

 

 

Report No. :

353802

Report Date :

14.12.2015

           

IDENTIFICATION DETAILS

 

Name :

STADA ARZNEIMITTEL GESELLSCHAFT M.B.H.

 

 

Registered Office :

Muthgasse 36/2, A-1190 Wien

 

 

Country :

Austria

 

 

Financials (as on) :

31.12.2014

 

 

Year of Establishment  :

1989

 

 

Legal Form :

Limited Liability Company

 

 

Line of Business :

Wholesale of pharmaceutical products

 

 

No. of Employee :

42 (2015)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Good 

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Austria

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

AUSTRIA - ECONOMIC OVERVIEW

 

Austria, with its well-developed market economy, skilled labor force, and high standard of living, is closely tied to other EU economies, especially Germany's. Its economy features a large service sector, a relatively sound industrial sector, and a small, but highly developed agricultural sector. Economic growth was anemic at less than 0.5% in 2013 and 2014, and growth in 2015 is not expected to exceed 0.5%. Austria's 5.6% unemployment rate, while low by European standards, is at an historic high for Austria. Without extensive vocational training programs and generous early retirement, the unemployment rate would be even higher. Public finances have not stabilized even after a 2012 austerity package of expenditure cuts and new revenues. On the contrary, in 2014, the government created a "bad bank" for the troubled nationalized "Hypo Alpe Adria" bank, pushing the budget deficit up by 0.9% of GDP to 2.4% and public debt to 84.5% of the GDP. Although Austria's fiscal position compares favorably with other euro-zone countries, it faces several external risks, such as Austrian banks' continued exposure to Central and Eastern Europe, repercussions from the Hypo Alpe Adria bank collapse, political and economic uncertainties caused by the European sovereign debt crisis, the current crisis in Russia/Ukraine, the recent appreciation of the Swiss Franc, and political developments in Hungary.

Source : CIA

Company name

 

STADA ARZNEIMITTEL GESELLSCHAFT M.B.H.

 

Muthgasse 36/2, A-1190 Wien

 

Phone:

(0043) 1 3678585

Fax:

(0043) 1 3678585 - 85

E-mail:

office@stada.at

Internet:

http://www.stada.at

 

 

Activities

 

ÖNACE 46461 100% Wholesale of pharmaceutical products

 

 

Financial data

 

Financial details can also be entered during the period, irrespective of the balance sheet date.

 

total turnover (total sales)

2015

EUR

19.000.000,00

(expected)

total turnover (total sales)

2014

EUR

18.776.385,25

(exact)

total turnover (total sales)

2013

EUR

17.339.631,53

(exact)

total turnover (total sales)

2012

EUR

15.515.360,51

(exact)

total turnover (total sales)

2011

EUR

14.186.443,35

(exact)

 

total investments

2014

EUR

33.624,44

(exact)

 

total company vehicles

2015

 

27

(approx.)

 

total employees

2015

 

42

(approx.)

white collar workers

2015

 

40

(approx.)

apprentices

2015

 

2

(approx.)

 

 

General company information

 

Company name

STADA Arzneimittel Gesellschaft m.b.H.

Year of incorporation

1989

Type of company

Wholesale and retail trade; repair of motor vehicles

Legal form

limited liability company since 1989-01-24

Companies house number

FN 52069 y Wien since 1989-02-13

Import

world-wide

Germany

2015

2015

DVR number

1020587

ARA-number

1553

VAT number

ATU 34739405

number - Austrian National Bank

1209507

Last balance sheet:

2014

Banking connection

RAIFFEISENLANDESBANK NIEDERÖSTERREICH-WIEN AG

BLZ 32000

main bank connection

 

 

Locations

 

operational

A-1190 Wien, Muthgasse 36/2

registered office

operational

A-1190 Wien, Muthgasse 36/2

registered headquarters, rented premises

 

0043 1 3678585

office@stada.at

former

A-1190 Wien, Heiligenstädterstraße 52/2/8

registered office

former

A-5081 Anif, Anif 36

registered office

former

A-1140 Wien, Penzingerstraße 41

registered headquarters

former

A-1190 Wien, Heiligenstädter Straße 52/2/8

office

former

A-5081 Anif, Anif 36

office

former

A-1190 Wien, Heiligenstädterstraße 52/2/8

registered headquarters

 

 

Private data

 

Surname

Date of birth

Address

Executive positions

Further executive positions (as registered in the companies' house)

Bernd Leiter

1962-04-14

A-1030 Wien

Am Modenapark 6

manager

1

Dr. Gabriele Hartl

1970-04-28

A-3021 Pressbaum

Ludwig-Hinnerth-Straße 11(c/o)

individual signing clerk

0

Dieter Fabich

 

A-1190 Wien

Muthgasse 36(c/o)

head of purchasing

0

Bernd Langmann

 

A-1140 Wien

Albert Schweitzergasse 3(c/o)

head of sales

0

Dr. Gabriele Hartl

 

A-1190 Wien

Muthgasse 36(c/o)

head of marketing

0

ownership structure and related companies

 

Company name

Address

Shareholdings in %

Since

Commercial register no.

Shares in this company are held by:

STADA Arzneimittel Aktiengesellschaft

D-61118 Bad Villbel

Stadastraße 2-18

100 %

1993-09-29

B 71290

 

 

Balance Sheet (absolute) all amounts in EUR

 

 

2014-12-31

Franchises, patents, licences, trademarks and similar rights and advantages

93.442,35

Sum intangible assets

93.442,35

 

Other operating and business equipment

32.369,12

Sum tangible assets

32.369,12

 

Sum fixed assets

125.811,47

 

Finished products

4.942.898,37

Outstanding service claims

4.507,62

Sum stock

4.947.405,99

 

Claims from delivered goods and performed services

730.476,34

Claims against related firmes Claims against companies with shareholding relationship

162.313,79

Other claims and assets

287.100,20

Sum claims

1.179.890,33

 

Cash on hand, cheques and bank deposits

1.818.183,07

Sum cash and bank

1.818.183,07

 

Sum current assets

7.945.479,39

 

Deferred charges

94.374,71

Sum deferred charges

94.374,71

Assets

8.165.665,57

 

Subscribed/declared capital

2.571.200,00

Not committed capital reserves

449.594,20

Free reserves

16.818,17

Balance sheet profit/balance sheet loss

2.091.448,53

Thereof profit/loss carried forward

1.177.026,47

Sum equity capital

5.129.060,90

 

Tax reserves

513.635,47

Other reserves

872.048,24

Sum reserves

1.385.683,71

 

Liabilities from delivered goods and performed services

836.937,32

Liabilities against related firms

617.894,09

Other liabilities

196.089,55

Sum liabilities

1.650.920,96

 

Liabilities and shareholders'equity

8.165.665,57

Balance sheet sum

8.165.665,57

 

 

P / L Account (absolute) all amounts in EUR

 

 

2014-12-31

Gross sales

18.776.385,25

Total turnover or gross profit

18.776.385,25

 

Other operating profits

1.040.676,98

Other operating profits totally

1.040.676,98

 

Costs for obtained services

-2.482.993,75

Material costs

-8.618.261,32

Costs for obtained services totally

-11.101.255,07

 

Salaries

-2.348.820,99

Costs for severance pays

-35.557,93

Legal fringe benefits and other payments depending on salaries

-574.813,67

Other social fringe benefits

-20.407,98

Personnel expenses totally

-2.979.600,57

 

Depreciation of intangible assets, tangible assets,activated expenses for the set up and expansion of business operation

-47.948,26

Depreciation tangible assets / intangible assets totally

-47.948,26

 

Other operating costs

-4.472.629,42

Total costs

-4.472.629,42

 

Operating result totally

1.215.628,91

 

Profits from shareholdings

3.575,87

Interest income, securties income and similar income

5.346,59

Interest and similar disbursements

-1.737,00

Financial profits totally

7.185,46

 

Results from usual business activity totally

1.222.814,37

 

Taxes on income and profits

-308.392,31

Taxes on income and profits totally

-308.392,31

 

Annual surplus/annual deficit totally

914.422,06

 

Annual profit/annual loss totally

914.422,06

 

Profit and loss carried forward from previous year

1.177.026,47

Transfer of profits totally

1.177.026,47

 

B/S profit/ B/S loss from profit and loss account

2.091.448,53

 

 

Key ratios

 

 

2014

Cashflow II

962.370,32

Debt amortisation period in years

1,26

Bank indebtedness

0,00

Equity capital share in %

62,81

Social capital share

0,00

Fixed assets coverage

4.076,78

Net profit ratio

6,51

Capital turnover

2,29

Return on investment in %

14,99

Cashflow in % of operating performance

5,12

Cashflow I

1.270.762,63

Gross productivity

6,30

Net productivity

2,57

Operating performance

18.776.385,25

Inventories in % of operating performance

26,34

Gross profit

7.675.130,18

 

 

Land Register

 

Note

No real estate property registered

 

 

Commercial register

 

Source of data from commercial register: Republic of Austria represented by the Federal Ministry of Justice

 

firm (style)

1      STADA Arzneimittel Gesellschaft m.b.H.

legal form

1      Gesellschaft mit beschränkter Haftung

registered office

7      politischer Gemeinde Wien

business adress

19      Muthgasse 36/2
1190 Wien

capital

23      EUR 2.571.200

reference date annual accounts

1      31. Dezember

annual accounts

32      zum 31.12.2014 eingereicht am 22.09.2015

power of representation

1      Die Generalversammlung bestimmt, wenn mehrere Geschäfts-
führer bestellt sind, deren Vertretungsbefugnis.
1   Gesellschaftsvertrag  vom 24.01.1989                                001
4   Generalversammlungsbeschluss  vom 13.05.1998                        002
Neufassung des Gesellschaftsvertrages.
7   Generalversammlungsbeschluss  vom 05.05.1999                        004
Änderung des Gesellschaftsvertrages in § 1
8   Generalversammlungsbeschluss  vom 23.11.1999                        005
Kapitalerhöhung um ATS 21.000.000,- .
Änderung des Gesellschaftsvertrages im § 4.
11   Gesellschaftsvertrag mit Generalversammlungsbeschluss               006
vom 13.09.2001
gemäß 1. Euro-JuBeG angepasst.
11   Generalversammlungsbeschluss  vom 13.09.2001                        007
Kapitalerhöhung um EUR 24,23.
Änderung des Gesellschaftsvertrages in den §§ 4, 9, 12 und
18.
23   Generalversammlungsbeschluss  vom 14.08.2008                        008
Kapitalerhöhung um EUR 500.000,-- durch Sacheinlage.
Änderung des Gesellschaftsvertrages im § 4
29   Verschmelzungsvertrag  vom 27.05.2013                               009
29   Generalversammlungsbeschluss  vom 27.05.2013                        010
Diese Gesellschaft wurde als
übernehmende Gesellschaft mit der
STADA GmbH
(FN 237553 v)
als übertragender Gesellschaft verschmolzen.
Sitz der übertragenden Gesellschaft in Mödling.

 

proxy

H   Dr. Gabriele Hartl, geb. 28.04.1970
31        vertritt seit 21.04.2015 selbständig

 

managing director

G   Bernd Leiter, geb. 14.04.1962
20        vertritt seit 04.09.2007 selbständig

 

shareholder

B   STADA - ARZNEIMITTEL
Aktiengesellschaft,
Bad Vilbel, BRD (HRB 1290 Amtsgericht
Bad Vilbel)
23        ....................  EUR 2.571.200
23        ...............................................  EUR 2.571.200
-------------------------------------------------------
Summen:           EUR 2.571.200              EUR 2.571.200

 

general table

Landesgericht Salzburg
1 Ersterfassung abgeschlossen am 29.09.1993  Geschäftsfall 913 Fr  1172/93 g
Ersterfassung gem. Art. XXIII Abs. 4 FBG
4 eingetragen am 24.07.1998                  Geschäftsfall  24 Fr  5515/98 a
Antrag auf Änderung  eingelangt am 16.07.1998
Handelsgericht Wien
7 eingetragen am 21.10.1999                  Geschäftsfall  71 Fr  7305/99 i
Antrag auf Sitzverlegung  eingelangt am 28.06.1999
8 eingetragen am 14.01.2000                  Geschäftsfall  73 Fr  5235/99 f
Antrag auf Änderung  eingelangt am 07.12.1999
11 eingetragen am 31.10.2001                  Geschäftsfall  73 Fr 13897/01 d
Antrag auf Änderung  eingelangt am 24.10.2001
17 eingetragen am 01.07.2006                  Geschäftsfall  73 Fr  7154/06 g
Antrag auf Änderung  eingelangt am 26.06.2006
19 eingetragen am 15.02.2007                  Geschäftsfall  73 Fr  1003/07 w
Antrag auf Änderung  eingelangt am 26.01.2007
20 eingetragen am 21.09.2007                  Geschäftsfall  73 Fr  9390/07 d
Antrag auf Änderung  eingelangt am 13.09.2007
23 eingetragen am 11.10.2008                  Geschäftsfall  75 Fr  9837/08 i
Antrag auf Änderung  eingelangt am 09.09.2008
29 eingetragen am 16.07.2013                  Geschäftsfall  71 Fr 10122/13 v
Antrag auf Änderung  eingelangt am 17.06.2013
31 eingetragen am 09.05.2015                  Geschäftsfall  71 Fr  4404/15 b
Antrag auf Änderung  eingelangt am 27.04.2015
32 eingetragen am 29.09.2015
Elektronische Einreichung Jahresabschluss  eingelangt am 22.09.2015

 

 

Historical development

 

Year of incorporation

1989

Date of registration

1989-02-13

 

 

Change in share capital

 

from

to

asset

 

 

2000-01-17

ATS

7.500.000,00

2000-01-17

2001-10-31

ATS

28.500.000,00

2001-10-31

2008-10-11

EUR

2.071.200,00

2008-10-11

 

EUR

2.571.200,00

 

 

Former executives

 

from

to

position

name

 

1997-08-30

manager

Dkfm. Christoph Küenburg

 

2002-12-18

manager

Dieter Rudolph

1999-10-21

2007-09-21

manager

Wolfgang Alfred Jeblonski

1997-08-30

2007-09-21

manager

Dr.med. Ulf Walter Robert Pangratz

2002-12-18

2007-09-21

manager

Hartmut Retzlaff

2006-07-01

2007-09-21

joint signing clerk

Bernd Leiter

 

 

Mergers

 

On

position

name

2013-07-16

merged with

STADA GmbH

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.66.99

UK Pound

1

Rs.101.78

Euro

1

Rs.73.47

EUR

1

Rs. 73.53

Note : Above are approximate rates obtained from sources believed to be correct

 

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

ASH

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

RR

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.